Addiction

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis

Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all dosesSignificant improvement in all signs and…

9 months ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™HOUSTON, TX, April 23, 2025…

9 months ago

Arialief Reviews And Complaints (INVESTIGATIVE REPORT) Safe Ingredients for Neuropathy Relief or Over Hype?

MIAMI, April 23, 2025 (GLOBE NEWSWIRE) -- Arialief is a nerve-support supplement that has recently seen a rise in popularity.…

9 months ago

Awakn Life Sciences Announces Shareholder Approval of Arrangement

Toronto, Ontario--(Newsfile Corp. - April 23, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn"…

9 months ago

Hazelden Betty Ford Foundation Launches Next-Generation Model of Care and Quality

Industry-leading approach harnesses unique set of resources to improve quality in mental health and substance use treatmentCenter City, Minnesota--(Newsfile Corp.…

10 months ago

Contrave Weight Loss: Top OTC Contrave Weight Loss Medication Alternative From PhenQ

Contrave is taken to help people lose weight. It is a combination of two medicines that work in the brain…

10 months ago

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

10 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company")…

10 months ago

Neural Therapeutics Strengthens IP Portfolio With a Patent Application

Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline DosesExtraction Technology Delivering Higher Yields and Greater…

10 months ago

Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement

Toronto, Ontario--(Newsfile Corp. - April 11, 2025) - Further to its press release dated February 27, 2025 and its management…

10 months ago